Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 22, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of HBV data at the following scientific conferences.
Discovery on Target: Targeting HBV, Sept 25, 2017, Boston, MA
Presentations Include:
- RNA Interference: A New Tool in the Toolbox for Treatment of HBV by Amy Lee, Senior Director, Research
- HBV Capsid Assembly Inhibitors by Rene Rijnbrand, Vice President, Head of Biology
Discovery on Target: Emerging Oligonucleotide Therapeutics, Sept 27-28, 2017, Boston, MA
Presentation Includes:
- RNAi Based Human Therapy for Chronic Hepatitis B Infection by Amy Lee, Senior Director, Research
These presentations will be available by visiting the Investor section of www.arbutusbio.com and selecting Events and Presentations.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604-419-3200
Email: [email protected]
Tiffany Tolmie
Manager, Investor Relations
Phone: 604-419-3200
Email: [email protected]
Media
David Schull
Russo Partners
Phone: 858-717-2310
Email: [email protected]
